3 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
Main: To evaluate the safety and effectiveness of the Exhale Drug-Eluting Stent (DES) to improve pulmonary function for homogeneous emphysema subjects with severe hyperinflation, in a prospective, randomized, Sham-controlled, double-blind, multi-…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…